Filing Details
- Accession Number:
- 0001214659-25-010280
- Form Type:
- 13D Filing
- Publication Date:
- 2025-07-09 20:00:00
- Filed By:
- William Anderson Wittekind
- Company:
- Renovaro Inc. (NASDAQ:RENB)
- Filing Date:
- 2025-07-10
- SEC Url:
- 13D Filing
Ownership Summary
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| William Anderson Wittekind | 5,606,644 | 12,526,552 | 5,606,644 | 12,526,552 | 18,133,196 | 8.0% |
Filing
|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 21)
|
Renovaro Inc. (Name of Issuer) |
Common Stock, par value $0.0001 per share (Title of Class of Securities) |
29350E104 (CUSIP Number) |
William Anderson Wittekind 8581 Santa Monica Blvd., #317 West Hollywood, CA, 90069 (424) 235-1810 Patrick T. McCloskey McCloskey Law PLLC, 260 Madison Avenue, 15th Floor New York, NY, 10016 646.970.0611 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
07/09/2025 (Date of Event Which Requires Filing of This Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
SCHEDULE 13D
|
| CUSIP No. | 29350E104 |
| 1 |
Name of reporting person
William Anderson Wittekind | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
 (b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
OO | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
UNITED STATES
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
18,133,196.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
8.0 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
IN |
Comment for Type of Reporting Person:
The number of shares disclosed in Rows 7 and 9 consist of (i) 3,265,757 shares owned by William Anderson Wittekind ("Wittekind"); (ii) 840,319 shares owned by Weird Science LLC ("Weird Science"); (iii) 633,921 shares owned by the William Anderson Wittekind 2020 Annuity Trust, a grantor retained annuity trust of which Wittekind is the sole trustee (the "Wittekind 2020 Annuity Trust"); (iv) 450,568 shares owned by the Dybul 2020 Angel Annuity Trust, a grantor retained trust of which Wittekind is the sole trustee (the "Dybul 2020 Annuity Trust"); (v) 50,000 shares owned by the Ty Mabry 2021 Annuity Trust, a grantor retained annuity trust of which Wittekind is sole trustee (the "Mabry 2021 Annuity Trust"); and (vi) 366,079 shares owned by the William Anderson Wittekind 2021 Annuity Trust, a grantor retained annuity trust of which Wittekind is the sole trustee (the "Wittekind 2021 Annuity Trust" and, together with the Wittekind 2020 Annuity Trust, the Dybul 2020 Annuity Trust and the Mabry 2021 Annuity Trust, the "Trusts"). In his capacity as the sole manager of Weird Science, Wittekind has sole voting and sole dispositive power over the shares owned by Weird Science. In his capacity as the sole trustee of the Trusts, Wittekind has sole voting power and sole dispositive power over the shares owned by the Trusts.
(2) The number of shares disclosed in Rows 8 and 12 consists of (i) 88,121 shares owned by Wittekind and Serhat Gumrukcu, Wittekind's spouse ("Gumrukcu"), as joint tenants with a right of survivorship ("JTWROS") and (ii) 12,438,431 shares owned by Gumrukcu, of which Wittekind shares voting and dispositive power through a power of attorney dated June 24, 2022. Pursuant to an order of the United States District Court for the District of Vermont dated October 27, 2023, the 12,438,431 shares owned by Gumrukcu are subject to a writ of attachment to secure the plaintiffs' claim in The Estate of Gregory Davis et al. v. Serhat Daniel Gumrukcu (Civil Case No. 5:22-cv-123).
(3) The percentage ownership disclosed in Row 13 is based upon (i) 172,7118,569 shares outstanding as of May 13, 2025, as disclosed in the Issuer's Form 10-Q filed with the Commission on May 15, 2025 plus (ii) 53,600,000 shares to be issued on or before July 11, 2025 upon conversion of convertible notes as reported in the Issuer's Form 8-K filed with the Commission on July 9, 2025.
SCHEDULE 13D
|
| Item 1. | Security and Issuer | |
| (a) | Title of Class of Securities:
Common Stock, par value $0.0001 per share | |
| (b) | Name of Issuer:
Renovaro Inc. | |
| (c) | Address of Issuer's Principal Executive Offices:
CENTURY CITY MEDICAL PLAZA, 2080 CENTURY CITY EAST, SUITE 906 LOS ANGELES,
CALIFORNIA
, 90067. | |
Item 1 Comment:
This Amendment No. 21 amends the Schedule 13D filed by Weird Science LLC, a California limited liability company ("Weird Science") and William Anderson Wittekind, a member and manager of Weird Science ("Wittekind") with respect to the shares of common stock, par value $0.0001 per share ("Common Stock") of Renovaro Inc. (the "Issuer") received by Weird Science pursuant to that certain Agreement and Plan of Merger dated January 12, 2018 (the "Merger Agreement") by and among the Issuer (then known as DanDrit BioTech USA, Inc.), DanDrit Acquisition Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Issuer ("Merger Sub"), Renovaro Biopharma, Inc., a Delaware corporation then known as Enochian Biopharma Inc. ("Target"), and Weird Science, in its capacity as the majority stockholder of the Target, as amended by Amendment Nos. 1 through 20 thereto. Wittekind is the sole reporting person under this Amendment No. 21 to Schedule 13D (the "Reporting Person").
Capitalized terms used but not defined in this Amendment No. 21 have the meanings given to such terms in the initial Schedule 13D, as amended by Amendment Nos. 1 through 20 thereto.
On Wednesday, July 9, 2025 the Issuer filed a Form 8-K with the Commission reporting that it would issue 53,600,000 shares of Common Stock on or before July 11, 2025 upon the conversion of convertible notes. Based upon the Issuer's Form 10-Q filed with the Commission on May 15, 2025, there were 172,118,569 shares of Common Stock issued and outstanding as of May 13, 2025. Effective as of the issuance of the 53,600,000 shares upon conversion of the convertible notes, the Reporting Person's beneficial ownership will decrease from the 10.4% reported in Amendment 20 to 8.0%. | ||
| Item 2. | Identity and Background | |
| (a) | William Anderson Wittekind | |
| (b) | 8581 Santa Monica Blvd., #317, West Hollywood, CA, 90069 | |
| Item 4. | Purpose of Transaction | |
Not Applicable. | ||
| Item 5. | Interest in Securities of the Issuer | |
| (a) | The information in Items 7-11 and Item 13 of the Cover Page of this Amendment No. 21, including the accompany notes, is hereby incorporated by reference into this Item 5(a). | |
| (b) | The information in Items 7-11 and Item 13 of the Cover Page of this Amendment No. 21, including the accompany notes, is hereby incorporated by reference into this Item 5(b). | |
| (c) | Not Applicable | |
| (d) | Not applicable | |
| (e) | Not applicable | |
| Item 6. | Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer | |
Not Applicable. | ||
| Item 7. | Material to be Filed as Exhibits. | |
Not applicable. | ||
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|